LOGIN
ID
PW
MemberShip
2023-12-07 12:21
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Company
Demand for ADC Enhertu rise despite nonreimbursement
by
Kim, Jin-Gu
Nov 30, 2023 05:55am
Cumulative sales of Daiichi Sankyo¡¯s HER2-positive breast cancer treatment ¡®Enhertu (trastuzumab-deruxtecan)¡¯ have exceeded KRW 10 billion even without reimbursement. According to the market research institution IQVIA on the 27th, Enhertu's cumulative sales were KRW 13.8 billion by Q3 this year. Sales steadily increased from KRW 2.2 bi
Company
Samsung Biologics¡¯ CMO orders exceed KRW 3 trillion this yr
by
Chon, Seung-Hyun
Nov 29, 2023 05:50am
Samsung Biologics announced on the 28th that its contract manufacturing organization (CMO) orders this year will exceed KRW 3 trillion. On the day, the company publicly announced that it signed 1 new and 4 expanded CMO deals. Samsung Biologics signed a CMO deal worth KRW 588.8 billion with Asian pharmaceutical companies. In addition,
Company
Korean companies bid to break AZ¡¯s monopoly with FcRN drug
by
Son, Hyung-Min
Nov 28, 2023 05:42am
With new FcRn antibody drugs secured by Korean pharmaceutical companies demonstrating efficacy in myasthenia gravis, these new FcRn antibody drugs are expected to rise as a competitor to C5 complement inhibitors such as AstraZeneca¡¯s Ultromiris and Soliris that currently occupy the market in Korea.
Company
Budesonide¡¯s price will be increased by up to 19%
by
Chon, Seung-Hyun
Nov 28, 2023 05:41am
The insurance ceiling price for asthma treatments containing ¡®budesonide¡¯ will be increased by up to 18.5%. The annual prescription market is expected to increase by more than KRW 1.5 billion. Once the supply and demand imbalance is resolved, the scope of market expansion is expected to increase further. According to the Ministry of Health
Company
Series of sales right transfers occur in KOR
by
Kim, Jin-Gu
Nov 27, 2023 06:07am
Competition between domestic pharmaceutical companies has been heating up for the rights to copromote vaccines by multinational pharmaceutical companies. With new products being released one after another in Korea, domestic companies are intent on becoming partners to secure these vaccines that generate stable cash flow. In fact, over
Company
CDK4/6 inhibitor mkt fluctuates with the rise of Kisqali
by
Son, Hyung-Min
Nov 27, 2023 06:06am
The CDK4/6 inhibitor market for breast cancer has changed from a monopoly to a duopoly in Korea. Kisqali, which had been introduced later into the market, has nearly caught up with Ibrance's sales. According to the market research institution IQVIA on the 24th, sales of Novartis¡¯s Kisqali had risen 95.2% YoY to reach KRW 12.1 billion in Q3 t
Company
New AD drug Adtralza enters last stage to reimb in KOR
by
Eo, Yun-Ho
Nov 27, 2023 06:06am
The atopic dermatitis treatment ¡®Adtralza¡¯ is entering its final stages of receiving reimbursement in Korea. According to industry sources, the Ministry of Health and Welfare recently issued a negotiation order for Leo Pharma Korea¡¯s interleukin-13 (IL-13) inhibitor for atopic dermatitis, Adtralza (tralokinumab). Under the order, the c
Company
Sales of K-anticancer drugs Leclaz and Rolontis rise in KOR
by
Chon, Seung-Hyun
Nov 24, 2023 05:37am
New anticancer drugs developed by domestic companies are gradually increasing their influence in their home market. Sales of Yuhan Corp¡¯s lung cancer treatment Leclaza are expected to exceed KRW 20 billion this year. Also, cumulative sales of Hanmi Pharmaceutical's neutropenia treatment Rolontis have exceeded KRW 10 billion just 2 two into its
Company
MSD vaccines will be sold by Boryung¡¤Kwangdong
by
Kim, Jin-Gu
Nov 24, 2023 05:37am
The domestic sales rights for 8 types of MSD vaccines have changed hands recently. Although HK Inno.N was in charge of joint sales for MSD vaccines in Korea, the vaccines will be separately sold by Boryung Biopharma and Kwangdong Pharmaceutical each. After signing a copromotion agreement with MSD for its vaccines at the end of 2021, HK
Company
Reimb for 7 of 13 Keytruda indications to be rediscussed
by
Eo, Yun-Ho
Nov 24, 2023 05:37am
Although it was well expected, the road to reimbursement extension for Keytruda is not going so smoothly. The company had applied to extend reimbursement for the drug to 13 additional indications in bulk earlier this year. According to industry sources, 4 indications of MSD Korea¡¯s PD-1 inhibitor Keytruda (pembrolizumab) for Triple-Neg
1
2
3
4
5
6
7
8
9
10
>